Pharma

  • EU Visa Mastercard card networks Europe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe

    Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”

    By Kristin Jensen • Sept. 23, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

    By • Sept. 22, 2026
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo talks up drug launches in effort to win back investors

    At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

    By • Sept. 21, 2026
  • DR. meeting with client
    Image attribution tooltip
    Permission granted by Walgreens
    Image attribution tooltip
    Sponsored by Walgreens Specialty Pharmacy

    Behind the outcomes: How whole-patient support is reshaping oncology care

    As oncology care grows personalized and home-based, support around treatment becomes as vital as treatment.

    Sept. 21, 2026
  • Female doctor talking with a diverse team of medical professionals during a meeting around a conference table in a hospital
    Image attribution tooltip
    Goodboy Picture Company via Getty Images
    Image attribution tooltip
    Sponsored by Lucid Group

    Are healthcare systems really ready for GLP-1s?

    New GLP-1 therapy indications mean new challenges for pharma companies, from care to consumer trust.

    Sept. 21, 2026
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo partners with Orbis, deepening investment in oral peptide drugs

    The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

    By • Sept. 17, 2026
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Roche, Dualitas team up to find bispecific drugs for immune diseases

    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

    By • Sept. 17, 2026
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis to pay $125M for blood-brain barrier crossing platform

    Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

    By • Sept. 16, 2026
  • OpenAI ChatGPT and Anthropic Claude application icons shown on screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

    The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."

    By Kristin Jensen • Sept. 16, 2026
  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca’s newly approved pill fails frontline breast cancer study

    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

    By • Sept. 14, 2026
  • A photo of Takeda president of R&D Andy Plump.
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

    Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”

    By Kristin Jensen • Sept. 10, 2026
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis RNA drug falls short in rare muscle disease study

    The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

    By • Sept. 8, 2026
  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Trailing rivals, AbbVie scores win with dual-acting myeloma drug

    The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

    By • Sept. 4, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: China deals, stock flatlines and Lilly’s M&A spree

    Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

    By • Sept. 4, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    GSK wagers up to $1.3B on a different kind of cancer drug

    With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

    By • Sept. 3, 2026
  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Akeso, Summit cancer drug confirms lung cancer survival benefit

    A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

    By • Sept. 3, 2026
  • The North Lawn at the White House in Washington, D.C.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Mid-cap biotechs join Trump’s latest round of drug pricing deals

    Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

    By • Sept. 1, 2026
  • Heart
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

    Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

    By • Aug. 28, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Biotech’s rebound is undeniable

    Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

    By • Aug. 28, 2026
  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    New data could widen use of AstraZeneca, Amgen immune disease drug

    Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

    By • Aug. 27, 2026
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test

    Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

    By Susan Kelly • Aug. 25, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Obesity drugs

    Roche commits to lean-mass preservation with Hanmi obesity deal

    For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

    By • Aug. 24, 2026
  • Promotional graphic for Season 2 of The Progress Profile: Alzheimer’s Research in Focus, featuring the Pearson and BioPharma Dive logos on a dark blue background with abstract glowing blue wave patterns on the right.
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

    This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

    By BioPharma Dive's studioID • Aug. 24, 2026
  • Doctor wearing lab coat using laptop
    Image attribution tooltip
    hirun via Getty Images
    Image attribution tooltip
    Sponsored by PharmaForceIQ

    Pharma marketers need a share-of-answer strategy before AI spend

    AI is changing how HCPs seek answers. Pharma marketers need a new strategy.

    Aug. 24, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Shareholder pressures Capricor; Lilly dives deeper into vaccines

    Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

    By BioPharma Dive staff • Aug. 21, 2026